A new pilot clinical study will explore the safety and effectiveness of 2 anti-canine monoclonal antibodies on solid tumors ...

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new ...

Market OverviewThe global Cancer Immunotherapy Market is valued at USD 121.4 Billion in 2024 and is projected to reach a ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

In an interview with Moneycontrol on July 14, Glenn Saldanha, Chairman and Managing Director of Glenmark, discussed the ...

A new treatment for advanced melanoma is showing promising results for people whose tumors have stopped responding to ...

Patients with migraine spontaneously described typical symptoms like pain but only revealed cognitive symptoms after being asked further questions, according to a speaker at the American Headache ...

Astria Therapeutics' Navenibart shows promise in phase 3 trials for hereditary angioedema. Click here to find out why ATXS ...

With ever-growing treatment options, clinical care access and a new focus on integrative strategies, cancer centers are constantly upgrading their services and options for patients. Becker’s asked ...

When Chloe Tatton boarded a flight to relocate to Dubai early last year, she hoped the change of climate might help ease her ...

Cullinan's innovative approach and Zipalertinib's potential approval in 2026 position it as a promising biotech investment.